Federal Circuit Upholds USPTO Authority to Estop Patentees from Obtaining Patent Claims 'Not Patentably Distinct' from Previously Invalidated Claims

October 3, 2024

Reading Time : 4 min

The Federal Circuit recently upheld the USPTO’s authority under the estoppel provision 37 C.F.R. § 42.73(d)(3)(i) to prohibit a patent owner from obtaining patent claims that are not patentably distinct from claims previously declared unpatentable in inter partes review (IPR) proceedings. However, the court clarified that the regulation applies only to new claims or amended claims, not previously issued claims.

Various phone manufacturers challenged the validity of different claims of U.S. Patent No. 7,461,353 (“the ’353 patent”) through a range of PTO proceedings, including ex parte and inter partes reexaminations, as well as a petition for IPR. The Board stayed all reexamination proceedings pending the outcome of the IPR. In its final written decision in the IPR, the Board found that each of the 18 challenged claims were unpatentable. The Federal Circuit affirmed that decision and the challenged claims were cancelled. However, 301 claims remained in the ’353 patent. As a result, the Board lifted the stays of the reexaminations and proceeded to consider the validity of the remaining claims. 

During the ex parte reexamination, patent owner submitted 107 amended claims, which were then deemed patentable over the prior art. Each amended claim combined limitations from claims previously found invalid in the IPR by, for example, combining the device of one claim together with the method of another.

In the inter partes reexaminations, the examiner rejected the majority of the remaining claims on obviousness grounds. On appeal, the Board reversed the examiner, but then rejected all pending claims, including both amended and previously issued claims, in view of 37 C.F.R. § 42.73(d)(3)(i). That regulation states: “A patent applicant or owner is precluded from taking action inconsistent with the adverse judgment, including obtaining in any patent: (i) a claim that is not patentably distinct from a finally refused or canceled claim.” According to the Board, each remaining claim was either essentially the same as a canceled claim or a combination of limitations that had been previously invalidated in the IPR. And because the claims were not “patentably distinct” from the invalidated claims, all claims must be deemed invalid.

On appeal, the patent owner challenged the Board’s decision on three grounds. First, it argued that the Board misinterpreted the regulation, giving it a broader scope than the common law rule of collateral estoppel. Second, the patent owner argued that the Board lacked statutory authority to implement a regulation that governed the estoppel effect of IPR decisions in subsequent PTO proceedings. Third, the patent owner argued that, as written, the regulation does not apply to previously issued claims. 

On the first argument, the Federal Circuit recognized the Board applied the term “patentably distinct” in the regulation as it had previously done in obviousness-type double patenting cases and in interference proceedings, and held this was the correct approach considering the similar purpose of the term in all three settings: to prohibit a patentee from exploiting patent claims that are materially indistinguishable from previously expired or invalidated claims. While the patent owner argued that “not patentably distinct” should be interpreted to mean “substantially the same,” and the court agreed that the two terms are equivalent, the Federal Circuit concluded that the outcome would be the same. 

As to patent owner’s second argument, that the regulation should be construed to adopt the common law principles of collateral estoppel, the Federal Circuit noted that the plain text of §42.73(d)(3)(1) goes beyond the common law rule of collateral estoppel by seeking a comparison between the claims an applicant was obtaining and the “finally refused or canceled claim.” 

This led to the question of whether the PTO has authority to implement §42.73(d)(3)(1). The Federal Circuit concluded that it does.  Under 35 U.S.C. § 316(a)(4), the USPTO is authorized to prescribe regulations “establishing and governing inter partes review . . . and the relationship of such review to other proceedings under this title.” Because the regulation prevents a patent owner or applicant from acting inconsistently with the outcome of an IPR proceeding, it “govern[s] inter partes review,” and falls under the authority granted by § 316(a)(4).

Finally, because patent owner did not make any specific arguments as to whether the amended claims were patentably distinct from the canceled claims, the Federal Circuit affirmed the Board’s application of §42.73(d)(3)(1) to the amended claims. 

However, the court sided with patent owner regarding its previously issued claims, holding that the Board’s application of §42.73(d)(3)(1) to previously issued claims, rather than only amended claims, was improper. As such, and due to the plain language in the regulation pertaining to “obtaining” a claim, the court vacated and remanded the Board’s decision as to the previously issued claims. 

Practice Tip: A patent holder attempting to overcome an adverse judgment in an IPR through reexamination should ensure that any new or amended claims are “patentably distinct” from the previously canceled claims. As a guide marker, the patent holder should determine whether a new or amended claim is non-obvious in that it “is more than the predictable use of the elements of the cancelled claims according to their established functions.” Likewise, a patentee should endeavor to do more than merely combine existing limitations to avoid the argument that the new or amended claims are nothing “more than the obvious sum of their parts.”  

Softview LLC v. Apple Inc., 108 F.4th 1366 (Fed. Cir. 2024).

Share This Insight

Previous Entries

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.